Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Other Non-Current Assets (2016 - 2025)

Viridian Therapeutics, Inc.\DE (VRDN) has 12 years of Other Non-Current Assets data on record, last reported at $1.5 million in Q3 2025.

  • For Q3 2025, Other Non-Current Assets rose 77.96% year-over-year to $1.5 million; the TTM value through Sep 2025 reached $1.5 million, up 77.96%, while the annual FY2024 figure was $501000.0, 17.05% down from the prior year.
  • Other Non-Current Assets reached $1.5 million in Q3 2025 per VRDN's latest filing, up from $506000.0 in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $1.5 million in Q1 2022 and bottomed at $1000.0 in Q1 2021.
  • Average Other Non-Current Assets over 5 years is $912947.4, with a median of $982000.0 recorded in 2022.
  • Peak YoY movement for Other Non-Current Assets: soared 154100.0% in 2022, then tumbled 44.34% in 2024.
  • A 5-year view of Other Non-Current Assets shows it stood at $1.5 million in 2021, then tumbled by 34.14% to $982000.0 in 2022, then crashed by 38.49% to $604000.0 in 2023, then decreased by 17.05% to $501000.0 in 2024, then soared by 202.99% to $1.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Assets were $1.5 million in Q3 2025, $506000.0 in Q2 2025, and $489000.0 in Q1 2025.